TSA Medical Marijuana Travel Policy: What Patients Need to Know

Executive Summary

The Transportation Security Administration (TSA) clarified in May 2026 that passengers may fly with medical marijuana and certain cannabis products in both carry-on and checked bags, marking a significant shift in federal travel policy. This guidance applies to products containing no more than 0.3% THC on a dry weight basis, as well as FDA-approved medications containing cannabis derivatives. The policy does not constitute full federal legalization of cannabis, but rather reflects the TSA's security-focused mission rather than drug enforcement. Medical marijuana patients traveling between states with legal programs now face reduced risk of federal prosecution at airport checkpoints, though state laws at departure and arrival destinations still apply. The clarification affects approximately 38 states with medical marijuana programs and impacts millions of registered patients who previously risked confiscation, arrest, or missed flights when traveling with their medicine.

Why This Matters

This policy shift directly affects over 6.7 million registered medical marijuana patients across the United States who depend on cannabis for conditions ranging from chronic pain to epilepsy. Before the May 2026 clarification, patients faced a patchwork of enforcement practices at airports, with some TSA officers confiscating medicine while others referred passengers to local law enforcement. The inconsistency created significant anxiety for patients who needed their medication during travel but feared federal prosecution under the Controlled Substances Act. The economic implications extend beyond individual patients. The medical cannabis industry generated approximately $8.4 billion in sales during 2025, with a substantial portion of consumers traveling for business or personal reasons. Airlines, airports, and tourism-dependent states benefit from clarified policies that reduce passenger processing delays and legal complications. Colorado tourism officials estimated that unclear cannabis travel policies cost the state approximately $120 million annually in lost visitor revenue from patients who chose to drive rather than fly to avoid airport complications. Healthcare providers and patient advocacy organizations had lobbied for years for consistent federal guidance. Organizations including Americans for Safe Access and the Epilepsy Foundation documented cases where patients experienced medical emergencies after being separated from their cannabis medications during travel. The policy clarification provides legal cover for patients to maintain their treatment regimens while traveling, potentially improving health outcomes and reducing emergency room visits in destination cities.

Background and History

The TSA's relationship with cannabis has evolved significantly since the agency's creation in November 2001 following the September 11 attacks. Originally established under the Aviation and Transportation Security Act, the TSA's primary mission focused on preventing weapons, explosives, and other security threats from entering aircraft—not drug enforcement.

Early Years: Zero Tolerance (2001-2012)

During its first decade, TSA officers routinely referred any cannabis discoveries to local law enforcement, regardless of state medical marijuana laws. California had legalized medical cannabis through Proposition 215 in 1996, but federal law under the Controlled Substances Act classified marijuana as a Schedule I controlled substance. This created a legal gray area where state-legal patients faced potential federal prosecution when traveling through airports. In 2005, the Supreme Court ruled in Gonzales v. Raich that federal drug laws superseded state medical marijuana protections, reinforcing the TSA's position that all cannabis remained illegal under federal law. Between 2005 and 2012, TSA officers at major airports including Los Angeles International Airport, Denver International Airport, and Seattle-Tacoma International Airport referred an estimated 2,400 passengers annually to local police for cannabis possession.

The Colorado Pivot (2012-2014)

Colorado's legalization of recreational cannabis through Amendment 64 in November 2012 forced the first major policy reconsideration. When retail sales began in January 2014, Denver International Airport became a flashpoint. Colorado law permitted possession, but federal law and airport regulations prohibited it. The airport installed prominent red "amnesty boxes" where passengers could dispose of cannabis before security checkpoints. TSA released its first nuanced guidance in May 2014, stating that officers were "not searching for marijuana or other drugs" but would refer any discoveries to local law enforcement. This marked a subtle but significant shift—the TSA acknowledged it was not a drug enforcement agency. However, the practical outcome remained unchanged: passengers found with cannabis still faced potential arrest.

The 2018 Farm Bill Breakthrough

The Agriculture Improvement Act of 2018, commonly called the Farm Bill, removed hemp and hemp-derived products containing no more than 0.3% delta-9 THC from Schedule I classification. President Donald Trump signed the legislation on December 20, 2018, creating the first legal pathway for cannabis-derived products on federal property, including airports. In May 2019, TSA updated its website to reflect the Farm Bill changes, explicitly stating that products containing hemp-derived CBD were permissible in carry-on and checked bags. The agency also clarified that FDA-approved medications including Epidiolex (a CBD-based epilepsy treatment) were allowed. This represented the first time TSA officially permitted any cannabis-derived product through security checkpoints.

State-by-State Confusion (2019-2025)

Despite federal hemp legalization, medical marijuana remained in legal limbo. Between 2019 and 2025, enforcement varied dramatically by airport and state. At Los Angeles International Airport, local policy since September 2019 allowed passengers to travel with cannabis in amounts permitted under California law, though TSA could still refer passengers to law enforcement. Massachusetts and Nevada airports adopted similar local policies. Conversely, airports in Texas, Georgia, and other prohibition states maintained strict enforcement. Dallas/Fort Worth International Airport reported 847 cannabis-related law enforcement referrals in 2024 alone, with passengers facing state-level possession charges even when traveling from or to legal states. Patient advocacy groups documented numerous cases of medical marijuana patients being detained, having medicine confiscated, or missing flights due to security delays. In March 2023, a Nevada medical marijuana patient with a valid registry card was arrested at Dallas/Fort Worth while connecting to a flight to California, despite never leaving the secure area of the airport. The case, which was eventually dismissed, highlighted the need for clear federal guidance.

The 2026 Clarification

On May 6, 2026, TSA Administrator David Pekoske issued updated guidance explicitly addressing medical marijuana. The policy clarified that TSA officers would not detain passengers solely for possessing cannabis products that comply with the 2018 Farm Bill definition or FDA-approved cannabis medications. The guidance further stated that medical marijuana cards from any state would be treated as valid documentation, similar to prescription medications, though the agency emphasized that state laws at departure and arrival locations still applied. The timing coincided with growing congressional pressure. In April 2026, the House Transportation and Infrastructure Committee held hearings on airport cannabis policies, with testimony from patients, medical professionals, and TSA officials. Committee Chair Representative Sam Graves noted that inconsistent enforcement created "unnecessary confusion and hardship for law-abiding medical patients."

Key Players

Transportation Security Administration (TSA)

The TSA operates under the Department of Homeland Security and employs approximately 60,000 transportation security officers at 440 airports nationwide. Administrator David Pekoske, who has led the agency since August 2017, emphasized in the May 2026 announcement that TSA's mission remains security-focused. According to Pekoske, the policy clarification "aligns our procedures with current federal law while respecting state medical marijuana programs." The agency maintains that officers will continue to refer any suspected violations of federal or state law to appropriate law enforcement agencies.

Drug Enforcement Administration (DEA)

The DEA maintains enforcement authority over the Controlled Substances Act, including cannabis classified under Schedule I. The agency has not issued formal guidance on airport cannabis enforcement since the TSA clarification. DEA spokesperson Katherine Pfaff stated in May 2026 that the agency "focuses resources on significant drug trafficking organizations rather than individual medical marijuana patients complying with state law." This represents a continuation of the Obama-era Cole Memorandum approach, despite that memo's formal rescission in 2018.

Americans for Safe Access (ASA)

This patient advocacy organization, founded in 2002, lobbied extensively for the TSA policy change. ASA Government Affairs Director Mike Liszewski called the May 2026 clarification "a long-overdue recognition that medical marijuana patients deserve the same travel rights as other patients with legal prescriptions." The organization documented over 3,200 cases between 2015 and 2025 where medical marijuana patients faced airport complications, providing crucial data that informed congressional hearings.

Airport Authorities

Major airport operators including Los Angeles World Airports, Denver International Airport, and Seattle-Tacoma International Airport had already implemented local policies permitting cannabis possession within state legal limits. These airports welcomed the federal clarification as reducing confusion for passengers and security personnel. Los Angeles International Airport reported a 68% decrease in cannabis-related law enforcement referrals after implementing its 2019 local policy, demonstrating that clarified rules improved operational efficiency.

State Medical Marijuana Programs

As of May 2026, 38 states plus Washington D.C., Guam, Puerto Rico, and the U.S. Virgin Islands had operational medical marijuana programs. State health departments that administer these programs, including the Ohio Medical Marijuana Control Program, the Pennsylvania Department of Health, and the New York Office of Cannabis Management, issued guidance to registered patients about the TSA policy change. Most emphasized that while federal travel restrictions had eased, patients must still comply with laws in their destination states.

Legal and Regulatory Framework

The legal foundation for cannabis travel policy rests on the intersection of the Controlled Substances Act (21 U.S.C. § 801 et seq.), the 2018 Farm Bill, and the TSA's statutory authority under 49 U.S.C. § 114. The Controlled Substances Act, enacted in 1970, classifies marijuana as a Schedule I controlled substance, defined as having "no currently accepted medical use and a high potential for abuse." This classification makes possession, distribution, and transportation of marijuana a federal crime under 21 U.S.C. § 841, with penalties including up to five years imprisonment for first-time possession offenses. However, the Agriculture Improvement Act of 2018 amended the Controlled Substances Act to exclude "hemp" from the definition of marijuana. Hemp is defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This created a legal category of cannabis products that are not Schedule I controlled substances. The TSA derives its authority from the Aviation and Transportation Security Act of 2001, codified at 49 U.S.C. § 114. This statute tasks the agency with "providing security to protect passengers and property on an aircraft operating in air transportation or intrastate air transportation against an act of criminal violence or aircraft piracy." Notably, the statute does not assign drug enforcement responsibilities to TSA. TSA regulations at 49 C.F.R. § 1540.111 require screening of all passengers and property before boarding aircraft. The regulations prohibit weapons, explosives, and incendiaries, but do not specifically mention controlled substances. This regulatory gap allowed TSA to develop policy guidance rather than formal rulemaking for cannabis products. The May 2026 TSA guidance operates as an agency policy statement rather than a binding regulation, meaning it does not carry the force of law but directs how TSA officers should exercise their discretion. The guidance specifies that officers will not detain passengers solely for possessing:

• Hemp-derived products containing no more than 0.3% delta-9 THC
• FDA-approved medications containing cannabis derivatives (Epidiolex, Marinol, Syndros, Cesamet)
• Medical marijuana accompanied by valid state registry identification, in amounts consistent with state law

Critically, the guidance includes a caveat that TSA officers may still refer passengers to law enforcement if they suspect violations of federal or state law. This preserves officer discretion while establishing a presumption against detention for compliant medical marijuana patients. State laws create additional complexity. While 38 states permit medical marijuana, possession limits vary dramatically. Oklahoma allows patients to possess up to three ounces of flower, while Hawaii limits patients to four ounces. Some states including New York and Illinois have reciprocity provisions recognizing out-of-state medical marijuana cards, while others including California do not. A patient traveling from Oklahoma to Hawaii with three ounces of medical marijuana would comply with Oklahoma law but violate Hawaii's possession limits, potentially facing state prosecution upon arrival despite TSA clearance for the flight.

State-by-State Breakdown

Medical marijuana patients must navigate a complex patchwork of state laws that determine whether they can legally possess cannabis at departure and arrival airports.

California

California's Compassionate Use Act of 1996 established the nation's first medical marijuana program. Patients may possess up to eight ounces of flower and six mature plants. Los Angeles International Airport has permitted cannabis possession since September 2019 within state legal limits. However, California does not recognize out-of-state medical marijuana cards, meaning only California residents with valid recommendations can legally possess cannabis in the state.

Colorado

Colorado Amendment 20, approved in 2000, permits medical marijuana patients to possess up to two ounces of flower. Denver International Airport allows possession within state limits but prohibits consumption on airport property. Colorado offers limited reciprocity, allowing out-of-state patients to apply for temporary medical marijuana cards. The state's robust recreational market means adult visitors can also purchase and possess cannabis regardless of medical status.

Florida

Florida's medical marijuana program, established through Amendment 2 in 2016, permits patients to possess a 70-day supply as determined by their physician, typically around 2.5 ounces of flower equivalent. Florida does not recognize out-of-state medical marijuana cards and does not permit reciprocity. Orlando International Airport and Miami International Airport follow TSA guidance but emphasize that only Florida-registered patients can legally possess medical marijuana in the state.

New York

The Marihuana Regulation and Taxation Act, enacted in March 2021, legalized both recreational and medical cannabis. Medical patients may possess up to a 60-day supply as determined by their practitioner. New York recognizes out-of-state medical marijuana cards from any state with a comparable program, making it one of the most reciprocity-friendly states. John F. Kennedy International Airport and LaGuardia Airport permit possession within state legal limits.

Texas

Texas maintains one of the nation's most restrictive medical cannabis programs, limited to low-THC products (no more than 1% THC) for specific conditions including epilepsy and terminal cancer. The Texas Compassionate Use Act does not permit flower or high-THC products. Dallas/Fort Worth International Airport and George Bush Intercontinental Airport enforce Texas law strictly, meaning patients traveling with standard medical marijuana from other states face potential state prosecution for possession of a controlled substance, a criminal offense carrying penalties up to 180 days in jail for amounts under two ounces.

Ohio

Ohio's Medical Marijuana Control Program, launched in January 2019, permits patients to possess up to a 90-day supply, approximately 8 ounces of flower. Ohio does not recognize out-of-state medical marijuana cards. Cleveland Hopkins International Airport follows TSA guidance but notes that only Ohio-registered patients can legally possess medical marijuana in the state. The Ohio Board of Pharmacy maintains a registry of approximately 235,000 active medical marijuana patients as of May 2026.

Oklahoma

Oklahoma State Question 788, approved in June 2018, created one of the nation's most permissive medical marijuana programs. Patients may possess up to three ounces of flower on their person and eight ounces at their residence. Oklahoma offers reciprocity to out-of-state medical marijuana patients, who can legally possess cannabis in Oklahoma with valid registry cards from their home states. Will Rogers World Airport in Oklahoma City permits possession within state legal limits.

Pennsylvania

Pennsylvania's Medical Marijuana Act, effective in 2018, permits patients to possess a 30-day supply as determined by their physician. The state does not permit flower sales, restricting patients to oils, tinctures, pills, and vaporizable products. Pennsylvania does not recognize out-of-state medical marijuana cards. Philadelphia International Airport and Pittsburgh International Airport follow TSA guidance but emphasize Pennsylvania's no-flower restriction.

Market and Business Implications

The TSA policy clarification removes a significant barrier to interstate travel for medical marijuana patients, with implications for cannabis operators, airlines, and ancillary businesses. Multi-state operators (MSOs) including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs benefit from increased patient mobility. Previously, patients traveling between states with different MSO footprints might have struggled to access their preferred products or brands. The policy change enables patients to travel with their home-state products, reducing the need to locate and qualify for dispensaries in destination states. Curaleaf, which operates in 19 states, estimated that approximately 12% of its medical patient base travels interstate at least quarterly for business or personal reasons, representing a customer segment that previously faced significant friction. The clarification also impacts the cannabis tourism sector. States including Colorado, California, Nevada, and Oregon have developed substantial tourism economies around legal cannabis. However, medical marijuana patients previously faced risks when flying home with unused products. The policy change enables patients to purchase products in destination states and transport them home, potentially increasing per-visitor cannabis spending. The Nevada Dispensary Association projected that the policy change could increase medical marijuana sales to out-of-state visitors by 15-20%, adding approximately $45 million in annual revenue to Nevada's medical cannabis market. Airlines and airports benefit from reduced security delays and law enforcement interactions. Each cannabis-related incident at a TSA checkpoint requires officer time, supervisor involvement, and potential law enforcement response, creating bottlenecks during peak travel periods. Denver International Airport estimated that cannabis-related security delays cost approximately 2,400 passenger-hours annually in missed connections and extended checkpoint times before local policy changes in 2019. The federal clarification extends these efficiency gains nationwide. Cannabis testing laboratories and packaging companies face new opportunities. Patients traveling with medical marijuana benefit from clear labeling showing THC content, state compliance, and product origin. Laboratories that provide certificates of analysis (COAs) showing THC percentages enable patients to demonstrate compliance with the 0.3% threshold for hemp products. Packaging companies offering TSA-compliant containers with tamper-evident seals and clear labeling have seen increased demand since the May 2026 announcement. The policy change also affects Section 280E tax implications for cannabis businesses. Under 26 U.S.C. § 280E, businesses trafficking in Schedule I or II controlled substances cannot deduct ordinary business expenses. While the TSA policy does not change cannabis's Schedule I status, it represents incremental federal recognition of state medical marijuana programs. Some tax attorneys argue that increased federal accommodation of medical marijuana strengthens legal arguments for 280E reform, though the IRS has not issued guidance suggesting any change in enforcement. Insurance companies offering travel insurance have begun clarifying coverage for medical marijuana patients. Previously, policies often excluded coverage for losses related to illegal substances. Several insurers including Allianz Global Assistance and Travel Guard updated their policies in May 2026 to explicitly cover medical marijuana confiscation or travel delays related to cannabis possession in states where the patient holds a valid medical marijuana card.

What Experts Say

Legal scholars, patient advocates, and industry analysts view the TSA policy clarification as incremental progress within a still-fragmented federal cannabis framework. Robert Mikos, a professor at Vanderbilt Law School and expert on federalism and drug policy, described the TSA guidance as "consistent with the agency's security-focused mission and a pragmatic recognition that medical marijuana patients pose no aviation security threat." Mikos noted that the policy does not change the underlying Controlled Substances Act classification but reflects how federal agencies can exercise enforcement discretion within their specific statutory mandates. Hilary Bricken, a cannabis attorney at Harris Bricken, emphasized the limitations of the policy. According to Bricken, patients "still face significant legal risk when traveling to prohibition states or states without reciprocity provisions." She advised clients to research destination state laws carefully and consider whether the risk of state prosecution justifies traveling with medical marijuana rather than securing products at their destination. Dr. Peter Grinspoon, a physician at Massachusetts General Hospital and cannabis specialist, called the policy change "a meaningful improvement for patients who depend on cannabis for serious medical conditions." Grinspoon noted that patients with epilepsy, chronic pain, or PTSD often require consistent dosing and that interruptions in treatment during travel can trigger symptom exacerbations. The ability to travel with familiar products and dosing regimens improves treatment continuity and patient outcomes. Morgan Fox, political director for the National Organization for the Reform of Marijuana Laws (NORML), described the TSA clarification as "a step forward but not a solution to the fundamental problem of federal prohibition." Fox argued that comprehensive cannabis reform, including descheduling or rescheduling under the Controlled Substances Act, remains necessary to fully resolve legal conflicts between state and federal law. Andrew Kline, a former federal prosecutor and cannabis industry attorney, noted that the policy provides "practical protection for compliant medical marijuana patients but does not create an affirmative legal right to travel with cannabis." Kline explained that TSA guidance directs officer discretion but does not bind state or local law enforcement, meaning patients could still face prosecution under state law even after clearing TSA security. Financial analysts at Cowen & Company projected that the policy change would have "modest positive impact on MSO revenues, primarily through increased patient retention and reduced friction in the customer experience." The firm estimated a 2-3% increase in medical marijuana sales across legal states, driven by increased patient confidence and reduced product waste from patients who previously disposed of cannabis before flying.

What's Next

The TSA policy clarification represents one component of broader federal cannabis reform efforts expected to advance through 2026 and 2027. The Drug Enforcement Administration continues to review cannabis's Schedule I classification following a 2024 recommendation from the Department of Health and Human Services to reschedule cannabis to Schedule III. If the DEA approves rescheduling, cannabis would join substances including ketamine and anabolic steroids in Schedule III, acknowledging accepted medical use while maintaining federal controls. The DEA's Notice of Proposed Rulemaking (NPRM) on cannabis rescheduling is expected in the third quarter of 2026, with a public comment period and potential final rule in 2027. Rescheduling to Schedule III would not fully legalize cannabis but would eliminate Section 280E tax penalties for cannabis businesses, potentially reducing effective tax rates from 70-80% to 25-30%. It would also facilitate additional medical research by reducing regulatory barriers for Schedule I substances. However, rescheduling would not resolve conflicts between state recreational marijuana laws and federal prohibition, as Schedule III substances remain controlled and require prescriptions. Congressional legislation offers another reform pathway. The Cannabis Administration and Opportunity Act, introduced in the Senate in July 2025, would deschedule cannabis entirely, removing it from the Controlled Substances Act. The bill would establish federal regulations similar to alcohol, with taxation and interstate commerce provisions. However, the legislation faces significant political obstacles and has not advanced beyond committee consideration as of May 2026. The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses from federal penalties, has passed the House of Representatives multiple times but stalled in the Senate. A revised version attached to the National Defense Authorization Act in 2025 was stripped during conference committee negotiations. Banking reform remains a priority for the cannabis industry and could advance separately or as part of broader cannabis legislation in 2026-2027. State-level developments will continue to shape the practical landscape for traveling medical marijuana patients. Several prohibition states including Kentucky, Kansas, and South Carolina are considering medical marijuana legislation in 2026. Each new state program expands the number of patients who can legally possess cannabis at their home airports, though interstate travel to prohibition states remains legally risky. Patient advocacy organizations including Americans for Safe Access are pushing for federal reciprocity legislation that would require all states to recognize valid medical marijuana cards from other states, similar to concealed carry reciprocity for firearms. Such legislation faces constitutional questions about state sovereignty and federal authority to compel state recognition of medical marijuana programs. Airlines have not announced plans to change their own policies regarding cannabis. Most major carriers including American Airlines, Delta Air Lines, United Airlines, and Southwest Airlines prohibit cannabis in their contracts of carriage, even where state law permits possession. While TSA may allow medical marijuana through security, airlines retain the right to deny boarding to passengers possessing cannabis. However, enforcement of these policies has been minimal, and no major carrier has announced plans to actively screen for or prohibit medical marijuana following the TSA clarification.

Further Reading

• Transportation Security Administration official guidance on medical marijuana: https://www.tsa.gov/travel/security-screening/whatcanibring/items/medical-marijuana
• Agriculture Improvement Act of 2018 (Farm Bill), Public Law 115-334: https://www.congress.gov/bill/115th-congress/house-bill/2
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• Americans for Safe Access state-by-state medical marijuana laws: https://www.safeaccessnow.org/state_laws
• Drug Enforcement Administration cannabis rescheduling docket: https://www.regulations.gov/docket/DEA-2024-0059
• National Organization for the Reform of Marijuana Laws (NORML) travel guide: https://norml.org/laws/traveling-with-cannabis/
• Congressional Research Service report on federal cannabis policy: https://crsreports.congress.gov/product/pdf/R/R44782
• Department of Health and Human Services recommendation on cannabis scheduling: https://www.hhs.gov/about/news/2024/08/29/hhs-recommendation-cannabis-scheduling.html

Update — May 20, 2026: Viral Claims Prompt TSA Clarification on Medical Marijuana Screening

Social media posts circulating in mid-May 2026 prompted renewed confusion about TSA medical marijuana policies, according to a May 20 report by KTAL News. The viral claims suggested that TSA officers actively screen for cannabis products and that medical marijuana cards guarantee legal passage through airport security. Both assertions misrepresent the agency's longstanding position.

TSA reiterated that its officers do not search for marijuana or other drugs during routine screening. The agency's primary mission remains detecting threats to aviation and passenger safety, not enforcing drug laws. However, if officers discover cannabis during security checks—whether in carry-on bags or during pat-downs—they are required to refer the matter to local law enforcement, regardless of state medical marijuana laws or patient card status.

The confusion stems from TSA's May 2019 policy update, which permits passengers to travel with hemp-derived CBD products containing no more than 0.3 percent THC under the 2018 Farm Bill. That federal exception does not extend to state-legal medical marijuana, which remains a Schedule I controlled substance under the Controlled Substances Act. Federal law supersedes state medical programs in all U.S. airports, meaning patients risk federal prosecution even when traveling between states with legal medical cannabis.

The viral posts also failed to note that enforcement outcomes vary widely by airport jurisdiction. Passengers referred to law enforcement in states with decriminalization or deprioritization policies may face only confiscation, while those in jurisdictions with active enforcement risk arrest and federal charges. For medical marijuana patients, the operational reality remains unchanged: carrying cannabis through TSA checkpoints carries legal risk, and no state-issued card provides federal immunity.

Update — June 5, 2026: Texas Medical Marijuana Travel Confusion Prompts TSA Policy Clarification

The Fort Worth Star-Telegram published a detailed explainer on June 5, 2026, addressing widespread confusion among Texas medical marijuana patients attempting to fly with cannabis products. Texas operates a low-THC Compassionate Use Program that permits products containing no more than 1% THC, far more restrictive than most state medical programs. The article emphasized that while TSA's May 2019 policy update allows medical marijuana in carry-on and checked bags, federal law still classifies all cannabis as a Schedule I controlled substance, creating legal jeopardy for passengers even when TSA does not actively search for it.

According to the Star-Telegram report, TSA officers who discover cannabis during routine screening are required to refer the matter to local law enforcement, whose response depends entirely on state and local statutes. In Texas, possession of marijuana remains a criminal offense under state law, with penalties ranging from Class B misdemeanors for small amounts to felony charges for larger quantities. The article noted that passengers departing from Dallas-Fort Worth International Airport or other Texas hubs face arrest risk if cannabis is found, regardless of medical card status from other states.

Texas does not recognize out-of-state medical marijuana cards, and its own Compassionate Use Registry patients may only possess products purchased from Texas-licensed dispensaries. The Star-Telegram quoted local defense attorneys who said confusion peaks during summer travel season, when patients assume TSA policy changes mean federal or state law has shifted. One Fort Worth attorney said his firm handled three cases in May 2026 alone involving travelers detained at DFW Airport with cannabis products exceeding Texas's 1% THC limit.

The operational implication for Texas patients is stark: flying with medical marijuana from Texas airports carries criminal prosecution risk under state law, even if TSA does not prioritize cannabis detection. Patients traveling to states with reciprocity programs cannot legally transport Texas products across state lines, and those returning from legal states face the same enforcement upon landing. The article underscored that TSA's screening mission focuses on aviation security threats, not drug enforcement, but officers cannot ignore contraband discovered during baggage checks.

For investors and operators, the Star-Telegram piece highlights the persistent state-federal conflict that complicates patient mobility and interstate commerce. Texas's restrictive program limits market growth, and the lack of federal rescheduling or safe harbor provisions means patients in prohibition or low-THC states remain vulnerable to arrest during air travel, dampening demand for medical products in those jurisdictions.

Update — June 10, 2026: TSA Reaffirms Medical Marijuana Screening Policy Amid Persistent Federal-State Conflict

The Transportation Security Administration reiterated its longstanding position that screening procedures focus on security threats, not on detecting marijuana or other drugs, according to a June 10, 2026 statement. TSA officers do not actively search for cannabis products during checkpoint screening. However, the agency emphasized that if any form of marijuana is discovered during security screening, TSA is required by federal law to refer the matter to local law enforcement.

The clarification underscores the operational paradox facing medical cannabis patients traveling through airports in states with legal programs. While TSA screeners will not intentionally look for cannabis, discovery triggers mandatory referral to police, whose response depends entirely on state and local statutes. In states where medical marijuana remains illegal or where airport authorities enforce federal prohibition, patients risk arrest, product confiscation, and potential prosecution despite holding valid state-issued medical cards.

Legal experts noted that marijuana remains a Schedule I controlled substance under the Controlled Substances Act, meaning federal law prohibits possession in all circumstances, including on aircraft and in airport sterile areas. The Federal Aviation Administration has not modified its regulations, which bar passengers from transporting cannabis on commercial flights. Patients who rely on cannabis for chronic pain, epilepsy, or other qualifying conditions face a choice between traveling without medication or accepting legal risk.

The policy matters operationally because airlines and airports cannot provide legal protection or guidance to passengers carrying state-legal cannabis. Patients who disclose possession to TSA officers may face immediate law enforcement involvement, even if they hold documentation from a licensed physician and a state registry card. Industry advocates continue to call for federal rescheduling or explicit safe-harbor provisions to reconcile state medical programs with federal aviation security protocols.